Some additional information:
Balance of restricted shares is 484,339,585 of which
-337,200,000 (70%) shares appear to be owned by officers and director
- 71,200,000 (15%) are in dispute with Savov in a lawsuit that the company appears to be prevailing
- 30,000,000 (6%) were issued from subscription agreement to 3 entities that the 144 aging process will be up in August 0f 2022
- 24,905,880 shares that were issued to other Bulgarians probably issued in association with the 2014-17 clinical trials and others that have not aged.
All of this information is in the OTC Filings. One just has to know what to look for and have a calculator.
There does not appear that any new shares will age into the float until the third quarter of 2022. With 70% of the restricted shares held by officers and 15% tied up in litigation there is only 15% of already issued common shares even possible to come in the float and in my opinion only 30 million are probable.